Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 2Other solid neoplasm 2Gynecologic 2Breast 1

Conditions

Breast Neoplasms 555Triple Negative Breast Neoplasms 94Inflammatory Breast Neoplasms 38Breast Neoplasms, Male 31Neoplasm Metastasis 27Ovarian Neoplasms 25Carcinoma, Non-Small-Cell Lung 23Melanoma 21Pancreatic Neoplasms 14Neoplasms 14Colorectal Neoplasms 13Carcinoma, Renal Cell 12Stomach Neoplasms 11Multiple Myeloma 10Lung Neoplasms 10Carcinoma, Ovarian Epithelial 9Carcinoma, Hepatocellular 9Lymphoma, Non-Hodgkin 8Sarcoma 7Lymphoma, Follicular 7Lymphoma 7Carcinoma, Ductal, Breast 7Recurrence 6Neutropenia 6Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Leukemia, Myeloid, Acute 6Leukemia, Lymphocytic, Chronic, B-Cell 6

Interventions

pembrolizumab 9Gemcitabine 5Cisplatin 5Nivolumab 3Drug Therapy 3budigalimab 2Paclitaxel 2Injections 2Docetaxel 2Carboplatin 2zenocutuzumab 1venetoclax 1tislelizumab 1spartalizumab 1seribantumab 1saracatinib 1rovalpituzumab tesirine 1pertuzumab 1pemigatinib 1niraparib 1nilotinib 1margetuximab 1lenvatinib 1futibatinib 1fludarabine 1entrectinib 1durvalumab 1crenigacestat 1cediranib 1bemarituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Cyclophosphamide × Breast × Clear all
NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
6 enrolled
BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡